Diabetes Telehealth Solutions: Improving Self-Management Through Remote Initiation of Continuous Glucose Monitoring
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The purpose of this study was to evaluate feasibility of initiating continuous glucose monitoring (CGM) through telehealth as a means of expanding access. Adults with type 1 diabetes (N = 27) or type 2 diabetes using insulin (N = 7) and interest in starting CGM selected a CGM system (Dexcom G6 or Abbott FreeStyle Libre), which they received by mail. CGM was initiated with a certified diabetes care and education specialist providing instruction via videoconference or phone. The primary outcome was days per week of CGM use during the last 4 weeks. Hemoglobin A1c (HbA1c) was measured at baseline and 12 weeks. Participant self-reported outcome measures were also evaluated. All 34 participants (mean age, 46 ± 18 years; 53% female, 85% white) were using CGM at 12 weeks, with 94% using CGM at least 6 days per week during weeks 9 to 12. Mean HbA1c decreased from 8.3 ± 1.6 at baseline to 7.2 ± 1.3 at 12 weeks (P < .001) and mean time in range (70-180 mg/dL, 3.9-10.0 mmol/L) increased from an estimated 48% ± 18% to 59% ± 20% (P < .001), an increase of approximately 2.7 hours/day. Substantial benefits of CGM to quality of life were observed, with reduced diabetes distress, increased satisfaction with glucose monitoring, and fewer perceived technology barriers to management. Remote CGM initiation was successful in achieving sustained use and improving glycemic control after 12 weeks as well as improving quality-of-life indicators. If widely implemented, this telehealth approach could substantially increase the adoption of CGM and potentially improve glycemic control for people with diabetes using insulin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237 · cited 1×
“0 mmol/L), which is the generally accepted target range for most adults with T1D or T2D (excluding pregnancy) [27].”
BackgroundSelf-citationContinuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 2×
“The amount of improvement in HbA1c and CGM-measured glycemic metrics was similar to that observed in clinic-based randomized trials [1, 8, 9, 11, 12, 28], but these results should be viewed in the context that this was a small feasibility study with no control group.”
BackgroundResultSelf-citationEffectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Lind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Schwarz, E., Ólafsdóttir, A. F., Frid, A., Wedel, H., et al. (2017) · JAMA · doi:10.1001/jama.2016.19976 · Cited by 705
Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651
Beck, R. W., Riddlesworth, T. D., Ruedy, K., Ahmann, A., Haller, S., Kruger, D., McGill, J. B., Polonsky, W., Price, D., Aronoff, S., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2855 · Cited by 635
Self-citationHaak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623
Heinemann, L., Freckmann, G., Ehrmann, D., Faber-Heinemann, G., Guerra, S., Waldenmaier, D., & Hermanns, N. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30297-6 · Cited by 522
The relationships between time in range, hyperglycemia metrics, and HbA1c
Beck, R. W., Bergenstal, R. M., Cheng, P., Kollman, C., Carlson, A. L., Johnson, M. L., & Rodbard, D. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818822496 · Cited by 479
Self-citationThe effect of continuous glucose monitoring in well-controlled type 1 diabetes
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0108 · Cited by 399
The Clinical Endocrinology Workforce: Current Status and Future Projections of Supply and Demand
Vigersky, R. A., Fish, L., Hogan, P., Stewart, A., Kutler, S., Ladenson, P. W., McDermott, M., & Hupart, K. H. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2257 · Cited by 238 · cited 3×
“Limited CGM awareness among primary care providers may be a factor responsible for the low rate of CGM adoption, particularly in areas where geography affects access to endocrinologists [19].”
BackgroundLittle, S. A., Leelarathna, L., Walkinshaw, E., Tan, H. K., Chapple, O., Lubina-Solomon, A., Chadwick, T. J., Barendse, S., Stocken, D. D., Brennand, C., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0030 · Cited by 237
A virtual type 2 diabetes clinic using continuous glucose monitoring and endocrinology visits
Dixon, R. F., Zisser, H., Layne, J. E., Barleen, N. A., Miller, D. P., Moloney, D. P., Majithia, A. R., Gabbay, R. A., & Riff, J. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819888662 · Cited by 80
Cited by
Comprehensive Telehealth Model to Support Diabetes Self-Management
Aleppo, G., Gal, R. L., Raghinaru, D., Kruger, D., Beck, R. W., Bergenstal, R. M., Cushman, T., Hood, K. K., Johnson, M. L., McArthur, T., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.36876 · Cited by 42
Self-citationKumbara, A. B., Iyer, A. K., Green, C. R., Jepson, L. H., Leone, K., Layne, J. E., & Shomali, M. (2023) · JMIR Diabetes · doi:10.2196/47638 · Cited by 29
“Participants in telehealth programs that incorporated RT-CGM reported an increased understanding of their diabetes [13], lower diabetes distress [16,18], and improved quality of life [16].”
Continuous Glucose Monitoring for Type 2 Diabetes: How Does It Compare with Type 1 Diabetes?
Beck, R. W., & Bergenstal, R. M. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0374 · Cited by 12
“28 The dramatic increase in telehealth visits during the COVID-19 pandemic also has demonstrated the value of CGM in diabetes management since CGM data can be readily available to facilitate effective virtual visits.”
Self-citationThe Expanding Use of Continuous Glucose Monitoring in Type 2 Diabetes
Dabbagh, Z., McKee, M. D., Pirraglia, P. A., Clements, K. M., Liu, F., Amante, D. J., Shukla, P., & Gerber, B. S. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0536 · Cited by 7
“42 Various members of a primary care team can participate.”
Metadata
- Authors
- Gal, R. L., Cohen, N. J., Kruger, D., Beck, R. W., Bergenstal, R. M., Calhoun, P., Cushman, T., Haban, A., Hood, K., Johnson, M. L., McArthur, T., Olson, B. A., Weinstock, R. S., Oser, S. M., Oser, T. K., Bugielski, B., Strayer, H., & Aleppo, G.
- Venue
- Journal of the Endocrine Society
- Publisher
- The Endocrine Society
- Published
- 2020-06-23
- Volume
- 4
- Issue
- 9
- Pages
- bvaa076-bvaa076
- ISSN
- 2472-1972 (ISSN-L)
- OpenAlex
- W3037935143
- Cited by
- 32
- References
- 15
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.